JPRN-UMIN000036867招募中未知
Plasma HER2 amplification in cell-free DNA to detect resistance to chemotherapy with anti-HER2 antibodies in gastric cancer - TROX Study-A2
Kyushu Study group of Clinical Cancer0 个研究点目标入组 84 人开始时间: 2019年5月28日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)A patient who has received a transfusion, blood product, or hematopoietic growth factor such as G-CSF up to 14 days prior to enrollment 2)The patient has severe drug hypersensitivity 3)The patient has peripheral neuropathy affecting the sensory nerves 4)The patient has an active infection 5)The patient has poorly controlled hypertension 6)The patient has poorly controlled diabetes 7)If a 12-lead ECG reveals marked ECG abnormalities up to 14 days prior to enrollment or the patient has heart disease that may pose a problem 8)The patient has severe pulmonary disease 9)The patient has a psychiatric disorder that may pose a problem or a history of central nervous system dysfunction 10)The patient has active gastrointestinal tract bleeding requiring repeated transfusions 11)The patient is receiving phenytoin, warfarin potassium, or flucytosine 12)The patient has moderate or more severe fluid accumulation in body cavities, such as pleural effusions and ascites, that continually requires treatment such as drainage 13)The patient has brain metastasis or clinical features suggesting brain metastasis 14)The patient has extensive bone metastasis 15)The patient has watery diarrhea 16)The patient has active multiple cancers 17)The patient has a history of receiving platinum-based antineoplastic agents 18)A woman who is pregnant, nursing, or possibly pregnant or a man who is trying to conceive with a partner 19)The patient tests positive for HBsAg or antibodies to HCV 20)A patient who is deemed to need antiviral therapy for HBV-related hepatitis 21)A lead investigator or the patient's primary physician otherwise deems that participation in this trial is not appropriate for the patient
研究者
相似试验
招募中
1 期
Study of Biological Effect in Tumor Samples from Clinical Trial Patients Treated with Ds8201Patients diagnosed with advanced or metastatic cancer treated with Trastuzumab Deruxtecan in the context of a clinical trial/expanded access/ compassionate use or standard treatment, irrespective of histologic type.CTIS2023-508830-33-00Solti Group180
进行中（未招募）
1 期
Enzalutamide assay in patients of the molecular group HER2-enriched with metastatic breast cancerMale or pre/post-menopausal women age = 18 years with advanced HR+/HER2-negative locally advanced/metastatic breast cancer resistant to endocrine therapy.EUCTR2019-002806-28-ESSOLTI40
已完成
不适用
Observational study of serum HER2 in HER2 positive advanced gastric cancer treated with trastuzumab in combination with capecitabine plus cisplatin(XP+H)Gastric cancerJPRN-UMIN000006445Sapporo Medical University 1st department of Internal Medicine10
已完成
不适用
Observational study of Serum HER2 in HER2 negative advanced gastric cancer treated with capecitabine plus cisplatin(XP)Gastric cancerJPRN-UMIN000006442Sapporo Medical University 1st department of Internal Medicine50
尚未招募
不适用
To study HER-2/neu over expression in gall bladder cancersCTRI/2022/10/046831MGUMST